Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Kura Oncology (Nasdaq: KURA) announced that management will present at three healthcare investor conferences in September 2026: Wells Fargo Healthcare Conference on September 8 at 3:45 p.m. ET, Cantor Global Healthcare Conference on September 9 at 9:10 a.m. ET, and Morgan Stanley Global Healthcare Conference on September 16 at 7:45 a.m. ET. Live audio webcasts and replays will be available in the Investors section of Kura’s website.
"Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways"
A small molecule is a low-weight chemical compound that can enter cells easily and interact with specific proteins or biological pathways to change how they work, much like a small key fitting into a lock. Investors care because small molecules are a common and often faster route to develop medicines, can be manufactured at scale, and may offer clearer regulatory and commercial paths compared with larger biologic therapies, affecting potential costs, timelines and returns.
menin inhibitormedical
"the FDA-approved once-daily, oral menin inhibitor for the treatment of adults"
A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.
NPM1-mutated acute myeloid leukemiamedical
"adults with relapsed or refractory NPM1-mutated acute myeloid leukemia"
A subtype of acute myeloid leukemia (AML) defined by a mutation in the NPM1 gene, which alters how blood-cell precursors behave and is detected by genetic testing. It matters to investors because the presence of this mutation affects prognosis, which patients are eligible for particular therapies or clinical trials, and therefore shapes drug development strategies, market size estimates, and regulatory pathways—similar to how a specific defect in a car model determines repair options and parts demand.
farnesyl transferase inhibitionmedical
"advancements in menin inhibition and farnesyl transferase inhibition"
Blocking the enzyme farnesyl transferase, which normally attaches a small lipid “farnesyl” tag to certain proteins so they can stick to cell membranes and send growth signals. Think of it like preventing a postage stamp from being added so a letter can’t be delivered to the right address. As a drug mechanism, it matters to investors because clinical trial outcomes, safety data, and regulatory decisions about these inhibitors can materially affect the value of companies developing them.
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:
Wells Fargo Healthcare Conference September 8, 2026 3:45 p.m. ET / 12:45 p.m. PT
Cantor Global Healthcare Conference September 9, 2026 9:10 a.m. ET / 6:10 a.m. PT
Morgan Stanley Global Healthcare Conference September 16, 2026 7:45 a.m. ET / 4:45 a.m. PT
Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following all three events.
About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Kura Oncology (KURA) present at the Wells Fargo Healthcare Conference 2026?
Kura Oncology will present at the Wells Fargo Healthcare Conference on September 8, 2026, at 3:45 p.m. ET / 12:45 p.m. PT. According to Kura Oncology, a live audio webcast and replay will be accessible via the Investors section of its website.
What is the schedule for Kura Oncology (KURA) at the Cantor Global Healthcare Conference 2026?
Kura Oncology is scheduled to present at the Cantor Global Healthcare Conference on September 9, 2026, at 9:10 a.m. ET / 6:10 a.m. PT. According to Kura Oncology, investors can access a live webcast and archived replay on the company’s website.
When is Kura Oncology (KURA) presenting at the Morgan Stanley Global Healthcare Conference 2026?
Kura Oncology will present at the Morgan Stanley Global Healthcare Conference on September 16, 2026, at 7:45 a.m. ET / 4:45 a.m. PT. According to Kura Oncology, the presentation will be webcast live with a replay available afterward online.
How can investors access Kura Oncology (KURA) webcasts for the September 2026 conferences?
Investors can access all three conference presentations via live audio webcasts in the Investors section of Kura Oncology’s website. According to Kura Oncology, archived replays will also be available following each event for on-demand listening.
What does Kura Oncology (KURA) do and what is KOMZIFTI (ziftomenib)?
Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer. According to Kura Oncology, it developed and commercializes KOMZIFTI (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.
What therapeutic areas are targeted by Kura Oncology’s pipeline as of September 2026?
Kura Oncology’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways. According to Kura Oncology, its programs aim to address high-need hematologic malignancies and solid tumors, including continued work in menin inhibition and farnesyl transferase inhibition.
